Tags

Type your tag names separated by a space and hit enter

Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.
Korean J Hepatol 2011; 17(3):183-8KJ

Abstract

BACKGROUND/AIMS

The reappearance rates of hepatitis C virus (HCV) RNA after a sustained virological response (SVR) have been reported to be 1-2%. We investigated the reappearance rate of HCV RNA after SVR in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN) and ribavirin.

METHODS

In total, 292 CHC patients who achieved an SVR after PEG-IFN and ribavirin treatment were included. They were treated with subcutaneous injections of either PEG-IFN-α 2a or 2b plus ribavirin orally. Liver function tests and qualitative HCV RNA assays were performed every 6 months during the follow-up period after an SVR.

RESULTS

Among the 292 patients, 224 (genotype 1, 92; genotype non-1, 132) were followed up for more than 6 months after SVR. These 224 patients were aged 48.1±11.5 years (mean±SD), and 129 of them were male. The median follow-up duration was 18 months (range 6-60 months). The reappearance rate of HCV RNA during follow-up was 0%. Two patients who achieved an SVR developed hepatocellular carcinoma during the follow-up period.

CONCLUSIONS

An SVR was maintained in all CHC patients treated with PEG-IFN plus ribavirin during a median follow-up of 18 months. However, a screening test for hepatocellular carcinoma is needed for patients with an SVR.

Authors+Show Affiliations

Department of Internal Medicine, Inje University Pusan Paik Hospital, Inje University College of Medicine, Busan, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22102384

Citation

Choi, Sang Bun, et al. "Durability of a Sustained Virological Response in Chronic Hepatitis C Patients Treated With Pegylated Interferon Alfa and Ribavirin." The Korean Journal of Hepatology, vol. 17, no. 3, 2011, pp. 183-8.
Choi SB, Lee YJ, Lee JI, et al. Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. Korean J Hepatol. 2011;17(3):183-8.
Choi, S. B., Lee, Y. J., Lee, J. I., Song, Y. J., Choi, B. J., Kim, J. H., ... Seol, S. Y. (2011). Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. The Korean Journal of Hepatology, 17(3), pp. 183-8. doi:10.3350/kjhep.2011.17.3.183.
Choi SB, et al. Durability of a Sustained Virological Response in Chronic Hepatitis C Patients Treated With Pegylated Interferon Alfa and Ribavirin. Korean J Hepatol. 2011;17(3):183-8. PubMed PMID: 22102384.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. AU - Choi,Sang Bun, AU - Lee,Youn Jae, AU - Lee,Jae Ik, AU - Song,Young Jin, AU - Choi,Byoung Jin, AU - Kim,Jong Han, AU - Jung,Eun Uk, AU - Park,Sung Jae, AU - Lee,Sang Heon, AU - Kim,Ji Hyun, AU - Choi,Jung Sik, AU - Jee,Sam Ryong, AU - Seol,Sang Yong, PY - 2011/11/22/entrez PY - 2011/11/22/pubmed PY - 2012/3/17/medline SP - 183 EP - 8 JF - The Korean journal of hepatology JO - Korean J Hepatol VL - 17 IS - 3 N2 - BACKGROUND/AIMS: The reappearance rates of hepatitis C virus (HCV) RNA after a sustained virological response (SVR) have been reported to be 1-2%. We investigated the reappearance rate of HCV RNA after SVR in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN) and ribavirin. METHODS: In total, 292 CHC patients who achieved an SVR after PEG-IFN and ribavirin treatment were included. They were treated with subcutaneous injections of either PEG-IFN-α 2a or 2b plus ribavirin orally. Liver function tests and qualitative HCV RNA assays were performed every 6 months during the follow-up period after an SVR. RESULTS: Among the 292 patients, 224 (genotype 1, 92; genotype non-1, 132) were followed up for more than 6 months after SVR. These 224 patients were aged 48.1±11.5 years (mean±SD), and 129 of them were male. The median follow-up duration was 18 months (range 6-60 months). The reappearance rate of HCV RNA during follow-up was 0%. Two patients who achieved an SVR developed hepatocellular carcinoma during the follow-up period. CONCLUSIONS: An SVR was maintained in all CHC patients treated with PEG-IFN plus ribavirin during a median follow-up of 18 months. However, a screening test for hepatocellular carcinoma is needed for patients with an SVR. SN - 2093-8047 UR - https://www.unboundmedicine.com/medline/citation/22102384/Durability_of_a_sustained_virological_response_in_chronic_hepatitis_C_patients_treated_with_pegylated_interferon_alfa_and_ribavirin_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22102384/ DB - PRIME DP - Unbound Medicine ER -